Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Target Price at $38.21

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $39.2778.

Several analysts have issued reports on the stock. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and upped their price target for the company from $32.00 to $43.00 in a report on Wednesday. Truist Financial began coverage on shares of Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright lifted their price objective on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. New Street Research set a $43.00 target price on Genmab A/S in a research note on Wednesday. Finally, BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd.

Get Genmab A/S alerts:

Check Out Our Latest Stock Analysis on Genmab A/S

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently made changes to their positions in the stock. Personal CFO Solutions LLC boosted its stake in shares of Genmab A/S by 3.7% during the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares during the last quarter. Founders Capital Management raised its stake in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Parallel Advisors LLC raised its stake in Genmab A/S by 11.3% in the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after purchasing an additional 419 shares during the last quarter. CWM LLC lifted its holdings in Genmab A/S by 18.8% in the 4th quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Genmab A/S stock opened at $28.87 on Friday. The firm has a market capitalization of $18.00 billion, a PE ratio of 21.87, a P/E/G ratio of 1.85 and a beta of 0.84. Genmab A/S has a 52 week low of $21.00 and a 52 week high of $35.43. The firm’s 50-day simple moving average is $26.82 and its 200 day simple moving average is $28.32. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

About Genmab A/S

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.

Featured Stories

• Five stocks we like better than Genmab A/S
• AMD and Cerbras Create A New Blueprint For Hardware
• Intel Earnings Reveal Whether the Chip Selloff Created a Buy
• CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
• Plugging In: How Kinder Morgan Powers Up Profits

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.